Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XE7A | ISIN: CA4990531069 | Ticker-Symbol: 04K
Tradegate
25.03.24
16:49 Uhr
3,580 Euro
-0,140
-3,76 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KNIGHT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KNIGHT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6803,76014:34
3,6603,76014:32

Aktuelle News zur KNIGHT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrKnight Therapeutics is still undervalued, Raymond James says2
FrEarnings call: Knight Therapeutics announced record revenues of $343 million1
21.03.Knight Therapeutics Inc: Knight Therapeutics loses $16.83-million in 20231
21.03.Knight Therapeutics GAAP EPS of -C$0.23, revenue of C$74.2M1
21.03.Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results117MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...
► Artikel lesen
14.03.Knight Therapeutics Inc: Knight Therapeutics to release 2023 results March 211
14.03.Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call1
06.03.Feeling GUD: Raymond James raises price target on Knight Therapeutics2
29.02.Stocks in Play: Knight Therapeutics Inc.,1
29.02.Knight Therapeutics launches Minjuvi in Brazil1
29.02.Knight Therapeutics Announces Launch of Minjuvi in Brazil99MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab)...
► Artikel lesen
28.02.Knight Therapeutics Inc. Celebrates its First Decade of Success2
21.02.Knight Therapeutics Inc: Knight applies for fostamatinib marketing nod in Brazil1
21.02.Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil335MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
► Artikel lesen
06.02.Knight Therapeutics Inc: Knight Therapeutics rolls out Bijuva capsules in Canada-
06.02.Knight Therapeutics Announces Launch of Bijuva in Canada246MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol...
► Artikel lesen
25.01.Knight Therapeutics Inc: Knight Therapeutics licenses IPX203 from Amneal3
25.01.Knight Therapeutics Inks License Agreement With Amneal Pharma For IPX2032
25.01.Amneal Pharma inks licensing pact with Knight Therapeutics3
25.01.Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203164MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1